What was particularly striking was its ability to normalise blood sugar levels which was observed in more than half of the diabetic patients in the trial
However, a new study has revealed the use of GLP-1 agonists do in fact reduce AMD risk among patients with obesity but not diabetes, compared to other weight-loss drugs
People who used Ozempic had an average weight loss of about 17%
However, new research has found that up to one in 10 people may have genetic variants that make them resistant to the effects of these drugs
Individual variation : Some patients may respond to lower doses due to individual pharmacokinetic or pharmacodynamic differences, but this should be assessed through proper clinical monitoring, not self-experimentation
Hence, they ensure to provide a personalized approach to weight loss, selecting the most suitable GLP-1 injection based on individual tolerance, treatment goals, lifestyle, and potential side effects